查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1562499

癌症免疫療法市場規模、佔有率、成長分析、按產品類型、按應用、按最終用戶、按地區 - 行業預測，2024-2031

Cancer Immunotherapy Market Size, Share, Growth Analysis, By Product Type (Monoclonal Antibodies, Vaccines), By Application (Breast Cancer, Lung Cancer), By End User (Hospitals, Clinics & Others), By Region - Industry Forecast 2024-2031
出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2022年，全球癌症免疫治療市場規模為1,254億美元，從2023年的1,359.3億美元成長到2031年的2,591.6億美元，預計在預測期內（2024-2031年）將成長。為8.4%。

由於幾個關鍵因素，預計全球癌症免疫治療市場將在預測期內顯著成長。相對於傳統治療方法，向標靶治療的轉變，加上對單株抗體 (mAB) 的需求不斷增加以及世界各地各種生物相似藥的推出，預計將推動市場擴張。這些創新藥物旨在增強人體的免疫反應來對抗癌症，並在很大程度上依賴新的分子發現。預計這一趨勢將對未來幾年的市場成長和需求產生積極影響。此外，市場也可能受益於美國食品藥物管理局（FDA）等監管機構核准的增加。例如，PD-1和CTLA-4查核點抑制劑的核准用於治療黑色素瘤和非小細胞肺癌（NSCLC）預計將進一步推動市場成長。一個著名的例子是 FDA核准Amgen 的 Lumaclas。該藥物針對患有與局部進行性或轉移性 NSCLC 相關的 KRAS G12C 突變的患者，作為該疾病的首個治療方法代表了突破。這些進步支撐了癌症免疫治療市場不斷成長的商機。

目錄

介紹

  • 研究目的
  • 定義
  • 市場範圍

調查方法

  • 資訊採購
  • 二手資料來源和主要資料來源
  • 市場規模預測
  • 市場假設與限制

執行摘要

  • 市場概況展望
  • 供需趨勢分析
  • 按細分市場的機會分析

市場動態及展望

  • 市場動態
    • 促進因素
    • 機會
    • 抑制因素
    • 任務
  • 波特的分析

主要市場考察

  • 技術分析
  • 價格分析
  • 價值鏈分析
  • 市場生態系統
  • 貿易分析
  • 供應鏈分析
  • 案例研究分析
  • 專利分析
  • 客戶和購買標準分析
  • 監管環境
  • 創新矩陣
  • 主要投資分析
  • 關鍵成功因素
  • 競爭程度

癌症免疫治療市場：依產品類型

  • 市場概況
  • 單株抗體
    • 裸單株抗體
    • 結合單株抗體
    • 雙特異性單株抗體
  • 疫苗
    • 預防性疫苗
    • 治療性疫苗
  • 查核點抑制劑
    • 細胞毒性 T 淋巴球相關蛋白 4 (CTLA-4)
    • 程序性細胞死亡 1 (PD-1) 和程序性細胞死亡配體 1 (PD-L1)
  • 細胞療法
    • 嵌合體抗原受體 (CAR) T 細胞療法
    • 樹突狀細胞
  • 免疫調節劑
    • 粒細胞巨噬細胞集落刺激因子（Gm-Csf 和 G-Csf）
    • 干擾素(IFN)
    • 白細胞介素(IL)
    • 溶瘤病毒
    • 免疫療法
    • 免疫是一種疾病
    • 作為盟友的免疫力
    • 核准的產品和臨床試驗

癌症免疫治療市場：依應用分類

  • 市場概況
  • 肺癌
  • 乳癌
  • 多發性骨髓瘤
  • 大腸直腸癌
  • 頭頸癌
  • 攝護腺癌
  • 惡性黑色素瘤
  • 其他癌症類型

癌症免疫治療市場：依最終用戶分類

  • 市場概況
  • 醫院
  • 診所/其他

癌症免疫治療市場規模：按地區分類

  • 市場概況
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 西班牙
    • 法國
    • 英國
    • 義大利
    • 其他歐洲國家地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地區
  • 中東和非洲 (MEA)
    • 海灣合作理事會國家
    • 南非
    • 其他中東/非洲地區

競爭格局

  • 前5名企業對比
  • 主要企業市場定位（2023年）
  • 主要市場參與者所採取的策略
  • 近期市集活動
  • 主要企業市場佔有率（2023年）

主要企業簡介

  • Amgen Inc.（US）
  • AstraZeneca（UK/Sweden）
  • Bayer AG（Germany）
  • Bristol-Myers Squibb（US）
  • Eli Lilly and Company（US）
  • Janssen Global Services, LLC（Johnson & Johnson）（US）
  • Merck & Co., Inc.（US）
  • Novartis（Switzerland）
  • Pfizer Inc.（US）
  • F. Hoffmann-La Roche Ltd（Switzerland）
  • Gilead Sciences, Inc.（US）
  • GlaxoSmithKline plc（UK）
  • AbbVie Inc.（US）
  • Regeneron Pharmaceuticals, Inc.（US）
  • Adaptimmune Therapeutics plc（UK）
  • Incyte Corporation（US）
  • Bluebird bio, Inc.（US）
  • BioNTech SE（Germany）
  • Immunocore Limited（UK）
  • CureVac NV（Germany）
  • BeiGene, Ltd.（China）
  • Zymeworks Inc.（Canada）
簡介目錄
Product Code: SQMIG35I2296

Global Cancer Immunotherapy Market size was valued at USD 125.4 billion in 2022 and is poised to grow from USD 135.93 billion in 2023 to USD 259.16 billion by 2031, growing at a CAGR of 8.4% during the forecast period (2024-2031).

The global market for cancer immunotherapy is projected to experience significant growth during the forecast period, driven by several key factors. The shift towards targeted therapies over traditional treatments, coupled with the increasing demand for monoclonal antibodies (mABs) and the introduction of various biosimilars worldwide, is expected to propel market expansion. These innovative drugs are designed to enhance the body's immune response to combat cancer, relying heavily on the discovery of new molecules. This trend is anticipated to positively impact market growth and demand in the coming years. Additionally, the market is set to benefit from growing approvals by regulatory bodies such as the U.S. Food and Drug Administration (FDA). For example, the approval of PD-1 and CTLA-4 checkpoint inhibitors for treating melanoma and non-small cell lung cancer (NSCLC) is expected to further drive market growth. A notable instance is the FDA's approval of Amgen's LUMAKRAS. This drug, designed for patients with KRAS G12C mutation associated with locally advanced or metastatic NSCLC, represents a groundbreaking development as it is the first-ever treatment for this condition. Such advancements underscore the expanding opportunities within the cancer immunotherapy market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cancer Immunotherapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cancer Immunotherapy Market Segmental Analysis

Global Cancer Immunotherapy Market is segmented by Product Type, Application, End user, and region. Based on Product Type, the market is segmented into Monoclonal Antibodies, Vaccines, Checkpoint Inhibitors, Cell Therapies, and Immunomodulators. Based on Application, the market is segmented into Lung Cancer, Breast Cancer, Multiple Myeloma, Colorectal Cancer, Head & Neck Cancer, Prostate Cancer, Melanoma, and Other Cancer Types. Based on End user, the market is segmented into Hospitals, and Clinics & Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Drivers of the Global Cancer Immunotherapy Market

The growing preference for immunotherapy over traditional treatments like radiation therapy and chemotherapy is expected to significantly drive the global cancer immunotherapy market in the coming years. Unlike radiation and chemotherapy, which primarily aim to destroy cancer cells through irradiation or surgery, these conventional methods often have the drawback of damaging healthy cells as well. This limitation has led to an increasing shift towards immunotherapy, which works by enhancing the body's own immune system using engineered proteins to target cancer cells more precisely. As a result, hospitals and surgical centers are increasingly adopting immunotherapy treatments due to their potential to reduce side effects and improve patient outcomes. This shift in treatment preference is fostering substantial growth in the global cancer immunotherapy market. By leveraging the body's natural defenses, immunotherapy offers a promising alternative that aligns with the evolving needs of healthcare providers and patients, thereby driving market expansion.

Restraints in the Global Cancer Immunotherapy Market

The high manufacturing costs and elevated prices of cancer immunotherapy treatments are significant factors that may impede the growth of the global market in the forecast period. The development and enhancement of these therapies require substantial resources and significant investment, which can slow market expansion. Additionally, limited medical access in remote and underserved areas, along with geographical barriers, could further restrict the awareness and availability of cancer immunotherapies. These challenges contribute to the slower adoption of these advanced treatments, potentially affecting overall market growth.

Market Trends of the Global Cancer Immunotherapy Market

Ongoing research into drugs designed to minimize side effects is anticipated to stimulate market growth. Additionally, the approval of PD-1 and CTLA-4 checkpoint inhibitors for treating melanoma and Non-Small Cell Lung Cancer (NSCLC) has significantly contributed to the market's expansion. The introduction of new forms of immunotherapy, including vaccines and adjuvants, is further fueling this growth. Moreover, the development and testing of additional immunotherapies, such as immunomodulators and CAR T-cell therapies, are showing promise for improving treatment outcomes. These advancements, coupled with new drug approvals, are expected to drive substantial growth in the cancer immunotherapy market throughout the forecast period.

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • Trade Analysis
  • Supply chain Analysis
  • Case study Analysis
  • Patent Analysis
  • Customer & Buying Criteria Analysis
  • Regulatory Landscape
  • Innovation Matrix
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Cancer Immunotherapy Market by Product Type

  • Market Overview
  • Monoclonal Antibodies
    • Naked Monoclonal Antibodies
    • Conjugated Monoclonal Antibodies
    • Bispecific Monoclonal Antibodies
  • Vaccines
    • Prophylactic Vaccines
    • Therapeutic Vaccines
  • Checkpoint Inhibitors
    • Cytotoxic T-Lymphocyte-Associated Protein-4 (CTLA-4)
    • Programmed Death 1 (PD-1) & Programmed Death Ligand 1 (PD-L1)
  • Cell Therapies
    • Chimeric Antigen Receptor (CAR) T Cell Therapy
    • Dendritic Cells
  • Immunomodulators
    • Granulocyte-Macrophage Colony-Stimulating Factor (Gm-Csf & G-Csf)
    • Interferons (IFN)
    • Interleukins (IL)
    • Oncolytic Virus
    • Immunotherapy
    • Immunity as an Obstacle
    • Immunity as an Ally
    • Approved Products & Clinical Trails

Cancer Immunotherapy Market by Application

  • Market Overview
  • Lung Cancer
  • Breast Cancer
  • Multiple Myeloma
  • Colorectal Cancer
  • Head & Neck Cancer
  • Prostate Cancer
  • Melanoma
  • Other Cancer Types

Cancer Immunotherapy Market by End User

  • Market Overview
  • Hospitals
  • Clinics & Others

Cancer Immunotherapy Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • Amgen Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca (UK/Sweden)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bayer AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bristol-Myers Squibb (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Eli Lilly and Company (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Janssen Global Services, LLC (Johnson & Johnson) (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Merck & Co., Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • F. Hoffmann-La Roche Ltd (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AbbVie Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Regeneron Pharmaceuticals, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Adaptimmune Therapeutics plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Incyte Corporation (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bluebird bio, Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BioNTech SE (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Immunocore Limited (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • CureVac N.V. (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BeiGene, Ltd. (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Zymeworks Inc. (Canada)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments